Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 11, 2009, Pages 1455-1464

  Fenske, Timothy S ^a   Hari, Parameswaran N ^a   Carreras, Jeanette ^a   Zhang, Mei Jie ^a   Kamble, Rammurti T ^b   Bolwell, Brian J ^c   Cairo, Mitchell S ^d   Champlin, Richard E ^e   Chen, Yi Bin ^f   Freytes, César O ^g   Gale, Robert Peter ^h   Hale, Gregory A ⁱ   Ilhan, Osman ^j   Khoury, H Jean ^k   Lister, John ^l   Maharaj, Dipnarine ^m   Marks, David I ⁿ   Munker, Reinhold ^o   Pecora, Andrew L ^p   Rowlings, Philip A ^q   Shea, Thomas C ^r   Stiff, Patrick ^s   Wiernik, Peter H ^t   Winter, Jane N ^u   Rizzo, J Douglas ^a   van Besien, Koen ^v   Lazarus, Hillard M ^w   Vose, Julie M ^x   more..

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h CELGENE CORPORATION   (United States)

ⁱ JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^j ANKARA UNIVERSITY   (Turkey)

^k EMORY UNIVERSITY   (United States)

^l WESTERN PENNSYLVANIA HOSPITAL   (United States)

^m South Florida Bone Marrow Stem Cell Transplant Institute   (United States)

ⁿ United Bristol Healthcare   (United Kingdom)

^o LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^p HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^q UNIVERSITY OF NEWCASTLE   (Australia)

^r UNIVERSITY OF NORTH CAROLINA   (United States)

^s LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^t NEW YORK MEDICAL COLLEGE   (United States)

^u NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^v UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^w UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^x UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

Autologous hematopoietic stem cell transplantation; Lymphoma; Rituximab

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; RITUXIMAB;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; KARNOFSKY PERFORMANCE STATUS; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; OVERALL SURVIVAL; THROMBOCYTE COUNT; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 70350587347     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.07.017     Document Type: Article

References (19)

1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
2. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-391.
3. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117-4126.
4. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027-5033.
5. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857-1861.
6. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
7. Hoerr AL, Gao F, Hidalgo J, et al. Effects of pre-transplant treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2004;22:4561-4566.
8. Klein JP, Moeschberger ML. Survival Analysis: Techniques For Censored And Truncated Data. New York: Springer; 2003.
9. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53.
10. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101:4279-4284.
11. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006;107:4207-4213.
12. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007;109:4930-4935.
13. Chaiwatanatorn K, Lee N, Grigg A, et al. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003; 121:913-918.
14. Motl SE, Baskin RC. Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review. Pharmacotherapy. 2005;25:1151-1155.
15. Benekli M, Hahn T, Shafi F, et al. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant. 2003;32:139-143.
16. Tarella C, Zanni M, Magni M, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for highrisk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol. 2008;26:3166-3175.
17. Sieniawski M, Staak O, Glossmann JP, et al. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Hematol. 2007;86:107-115.
18. Ashraf U, Mahajan R, Hahn R, et al. The effects of rituximab added to front-line or salvage chemotherapy in diffuse large B-cell lymphoma (DLBCL) undergoing high-dose chemotherapy (HDC) and autologous stem cell transplant (ASCT). Blood. 2008;112. abstract 1138.
19. Gisselbrecht C, Schmitz N, Mounier N, et al. R-ICE versus R-DHAPin relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stemcell transplantation and maintenance treatment with rituximab or not: First interim analysis on 200 patients. CORAL Study. Blood. 2007;110. abstract 517.